Share this Page:
Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the Kidney Cancer Programme, at the City of Hope Hospital, California talks about the changes in the management of renal cell carcinoma (RCC) over the past decade. He talks about combination treatments such as nivolumab with ipilimumab, which shows the potential for a complete response in about 10% of patients and durable responses in many more. He also talks about VEGF-TKI (axitinib) plus immunotherapy combinations with pembrolizumab and avelumab, as well as cabozantinib combinations with nivolumab and atezolizumab.
Read more in Practice Update here
Dr Jun Gong, Assistant Professor from Cedars-Sinai Medical Center, Los Angeles, California also talks about cabozantinib plus immunotherapy for the treatment of advanced RCC as one of the top stories for 2020, as well as the immunotherapy combinations, such as atezolizumab plus bevacizumab and nivolumab plus ipilimumab as potential treatments for non-clear cell RCC and sarcomatoid RCC.
